Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.82 |
| ▸ | DRD2 | P14416 | 14/20 | 0.82 |
| ▸ | HTR2A | P28223 | 4/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944275 | 0.92 | HTR1A (0.80) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL27909660 | 0.90 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL4194997 | 0.88 | HTR1A (1.00) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL27909555 | 0.87 | HTR1A (0.88) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL13944353 | 0.83 | DRD2 (0.79) | HTR1ADRD2HTR2ASLC6A4OPRM1 | |
| SCHEMBL27860653 | 0.83 | HTR1A (0.85) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL11786344 | 0.81 | HTR1A (0.85) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL4178633 | 0.79 | SLC6A4 (0.70) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL11313868 | 0.79 | HTR1A (0.75) | HTR1ADRD2HTR2ADRD1DRD3 | |
| SCHEMBL373815 | 0.79 | HTR1A (0.71) | HTR1ADRD2HTR2AOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | claimed |
| EP-1902044-A1 | 5-HTX MODULATORS | Bio Medisinsk Innovasjon AS (NO) | 2008-03-26 | — | — | EP | claimed |
| WO-2007007072-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2007-01-18 | — | — | WO | claimed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| WO-2007007072-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | HTR1A 4/4885DRD2 75/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.